Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances

Kardiologiya

Volumn 51, Issue 9, 2011, Pages 35-41

  Morozova, T E ^a   Ivanova, E P ^a   Rykova, S M ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cardiac rhythm disturbances; Chronic heart failure; Cytoprotection; Trimetazidine MB

Indexed keywords

TRIMETAZIDINE; VASODILATOR AGENT;

AGED; ARTICLE; CHRONIC DISEASE; COST; DISEASE MANAGEMENT; DRUG EFFECT; ECONOMICS; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MONITORING; REMISSION;

AGED; ARRHYTHMIAS, CARDIAC; CHRONIC DISEASE; COSTS AND COST ANALYSIS; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84856149530     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Essop M., Opie L. Metabolic therapy for heart failure. Eur Heart J 2004;25:1765-1768.
2. Kantor P., Luclen A., Kozak R., Lopaschuk G. The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circul Res 2000;86:580-588.
3. Lee L., Horowitz J., Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25. 634-641.
4. Cargnoni A., Pasini E., Ceconi C. et al. Insight into cytoprotection with metabolic agents. Eur Heart J 1999;1:40-48.
5. Szwed H., Pachocki R., Domzal-Bochenska M. et al. Efficacite et tolerance de la trimetazidine, antiangoreux hemodynamique dans l'angor d'effort stable. TRIMPOL I une etude multicentrique. Presse Med 2000;29:533-538.
6. Szwed H., Sadowsky Z., Pachocki R. et al.. Efficacy and safety oftrimetazidine in patients with stable angina under b-blocker therapy: TRIMPOL II - Multicenter study. Eur Heart J 1999;20:2516.
7. Ruzyllo W., Szwed H., Sadowski Z. et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20:1447-1454.
8. Brottier L., Barat J. L., Combe C. et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990;11:207-212.
9. Belardinelli R., Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164-2171.
10. Chierchia S. L. Trimetazidine and left ventricular ischaemic dysfunction: an overview of clinical evidence. Eur Heart J 2001;3(Suppl. 0):O16-O21.
11. Argaud L., Gomes L., Gateau-Roesch O. et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:983-999.
12. Bonello M., Sbragia P., Amabile S. et al. Protective effect of an acute oral loading dose of Trimetazidine on myocardial injury following percutaneus coronary intervention. Heart 2007;93:703-707.
13. Gupta R., Sawhney J. P. S., Narain V. S. Treatment of Stable Angina Pectoris with Trimetazidine Modified Release in Indian Primary-Care Practice. Am J Cardiovasc Drugs 2005;5:325-329.
14. Tritto I., Ambrosio G. et al. The Anti-Anginal Drug Trimetazidine Reduces Neutrophil-Mediated Cardiac Reperfusion Injury J Cardiovasc Pharmacol 2005;46:89-98.
15. Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003;7:661-672.
16. Rupp H., Zarain Herzberg A., Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;27:621-636
17. Labrou A., Giannoglou G., Ziotas D. et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7:143-150.